. Importantly, the mechanisms leading to the development of NEC in premature infants and the lessons learned from management of patients with NEC could have broad implications to other neonatal inflammatory processes 5, 6 . Despite several decades of experience in treating patients with NEC 5, 6 , the overall mortality and approach to treatment have remained largely unchanged since the initial descriptions of the disease several decades ago 3, 7 . Intensive research efforts over the past decade have begun to elucidate the molecu lar underpinnings of NEC and have identified several promising biologic strategies targeting the specific signalling pathways involved, which could potentially prevent and/or treat this disease in premature infants. Here, we will discuss current approaches to the diagnosis and treatment of NEC, review the current knowledge regarding its molecular pathophysiology and explore the advances made towards the development of specific preventive and treatment strategies.
Definitions and epidemiology of NEC Epidemiology and trends in the incidence of NEC. The current occurrence of NEC is in fact a manifest ation of the tremendous success achieved by neo natologists in their ability to keep premature infants alive at ever earlier gestational ages, with current global estimates of as many as 15 million babies born preterm every year, accounting for 11% of live births worldwide 1, 2, 8 . In the USA alone, the rate of prematurity is about 10% of all births, with rates as high as 13.23% in black individ uals of nonHispanic origin 9 . Large, population based and hospital based multi centre studies coordinated by neo natal research networks in Europe, North America, Australia and New Zealand have determined the incidence of NEC to be up to 13% among infants born ≤33 weeks of gestation or whose birth weight is ≤2,500 g 1, [10] [11] [12] [13] [14] [15] [16] [17] [18] . Interestingly, the incidence of NEC among extremely preterm neo nates in US academic centres has seen either a stabil ization or even a decline to about 9% in the past 5 years analysed 1 , a trend that might reflect increased vigilance and the implementation of standardized feeding strat egies 19 . Despite the fact that no predilection for sex, race or ethnicity has been conclusively established for NEC, a higher disease incidence is observed in male babies of Necrotizing enterocolitis: new insights into pathogenesis and mechanisms Diego F. Niño 1, 2 , Chhinder P. Sodhi 1, 2 and David J. Hackam 1, 2 Abstract | Necrotizing enterocolitis (NEC) is the most frequent and lethal disease of the gastrointestinal tract of preterm infants. At present, NEC is thought to develop in the premature host in the setting of bacterial colonization, often after administration of non-breast milk feeds, and disease onset is thought to be due in part to a baseline increased reactivity of the premature intestinal mucosa to microbial ligands as compared with the full-term intestinal mucosa. The increased reactivity leads to mucosal destruction and impaired mesenteric perfusion and partly reflects an increased expression of the bacterial receptor Toll-like receptor 4 (TLR4) in the premature gut, as well as other factors that predispose the intestine to a hyper-reactive state in response to colonizing microorganisms. The increased expression of TLR4 in the premature gut reflects a surprising role for this molecule in the regulation of normal intestinal development through its effects on the Notch signalling pathway. This Review will examine the current approach to the diagnosis and treatment of NEC, provide an overview of our current knowledge regarding its molecular underpinnings and highlight advances made within the past decade towards the development of specific preventive and treatment strategies for this devastating disease.
African American descent than in any other single demo graphic, which could be related to the higher incidence of prematurity in this demographic than in the general US population 9, 10, 12, 17, 20 . Modal disease onset occurs between 27-34 weeks after conception, with the high est incidence (13%) among infants with a birth weight <1,000 g 1, 7 . Furthermore, overall survival has not changed in the past five decades and the average mortality from NEC is 20-30%, with mortality as high as 50% in those infants requiring surgical management 21 . Although the majority of cases of NEC occur among premature infants, a small subset of babies born at term or shortly before (that is, ≥35 weeks of gestation) develop NEClike gastro intestinal signs and symptoms, frequently in association with other conditions 22 .
Factors affecting the susceptibility for NEC development in premature infants. Despite the complex and multifactorial nature of the pathogenesis of NEC, three major risk factors have been implicated in its develop ment: prematur ity, bacterial colonization of the gut and formula feeding 23 . Although no specific genetic pre disposition has been clearly associated with NEC, stud ies evaluating concordance rates in monozygotic and dizygotic twins have found a familial predisposition for the disease 24 . Moreover, evidence suggests that genetic variants leading to upregulated expression of downstream signalling regulators of Tolllike receptor 4 (TLR4), an innate immune receptor that recognizes lipopolysacchar ide found in Gramnegative bacteria, could result in increased susceptibility to the disease. These signalling regulators include nuclear factor κB1 (REF. 25 ), single Ig IL1related receptor 26 , the coreceptor molecule lymphocyte antigen 96 and the small glycolipid trans port protein ganglioside GM2 activator 27 . In addition, a single nucleotide polymorphism in the promoter region of IL18 (REF. 28) and genetic variants encoding proteins linked to the regu lation of the immune phenotype shift from type 1 to type 2 T helper cells 29 could all influence the risk of NEC develop ment. Other important clinical factors associated with NEC are summarized in BOX 1.
Diagnosis of NEC Clinical and radiographic markers. The cornerstone of effective NEC treatment relies on accurately diagnosing the disease, which can usually be established on the basis of readily available clinical, radiographic and lab oratory data. The typical neonate with NEC is a premature infant who is thriving, yet suddenly presents with feed ing intoler ance, abdominal distension, bloody stools and signs of sepsis (that is, changes in heart rate, respiratory rate, temperature and blood pressure) 5, 7 . An important consideration in the diagnosis of NEC is the gestational age at which these symptoms present, owing to the exist ence of an inverse relationship between gestational age and the onset and severity of symptoms in patients with NEC 30, 31 . Specifically, an infant born at ~27 weeks of ges tation will typically present with NEC at ~4-5 weeks of age and has a substantially higher risk of NEC develop ment than an infant born at closer to 37 weeks of ges tation, for whom onset typically occurs within the first 2 weeks after birth 13 . A late onset of NEC in the most premature infants might be related to delayed microbial colonization of the gut and establishment of virulent microbial agents, in part owing to the use of broad spectrum antibiotics and prolonged hospital stay [32] [33] [34] . Signs of sepsis can be associated with high gastric resid uals (defined as the volume that remains in the stomach before the next enteral feeding 35 ) of ≥2 ml/kg or >50% of the previous feeding volume, which could indicate the presence of feeding intolerance 35, 36 . Although feeding intolerance is the most common early gastro intestinal symptom associated with NEC 37 , some controversy persists as to the use of gastric residuals as an objective measure and their predictive value in the context of the disease progression, owing to the inherent variability in sampling gastric contents through a small nasogastric or orogastric tube, as well as to the lack of standardization in the procedure of obtaining gastric aspirates 36, 38 . For descriptive purposes and for disease stratifica tion, the Bell scoring system has been widely utilized, which assesses the degree of NEC severity as mild ( 5, 39 . Although no specific laboratory markers have been validated in making the diagnosis of NEC, neutropenia and thrombocytopenia are often present [40] [41] [42] . Consideration of alternative diag noses is critical for infants who present with NEC and in whom overlapping signs and symptoms might be present, including those who have spontaneous intes tinal perforation, ileus secondary to sepsis, sensitivity to cow milk, food protein intolerance, ischaemic bowel disease associated with heart disease or haematological disturbances (for example, polycythaemia).
Biomarkers and noninvasive testing for the diagnosis of NEC. The relative nonspecificity of the readily available clinical and radiographic tests described earlier in the
Key points
• Necrotizing enterocolitis (NEC) is the most common and devastating gastrointestinal disease affecting premature infants; overall NEC mortality has remained unchanged over the past 30 years owing to a lack of treatment options • The main risk factors for the development of NEC are prematurity, bacterial colonization and administration of formula feeds • The premature intestinal epithelium is predisposed to mounting an exaggerated inflammatory response to colonizing bacteria, leading to mucosal destruction and impaired mesenteric perfusion in the pathogenesis of NEC • The exaggerated inflammatory response is partially due to the increased expression of Toll-like receptor 4 (TLR4), which is expressed at high levels on the premature newborn intestinal epithelium • Increased expression of TLR4 in the intestinal epithelium of the premature gut reflects the surprising function that TLR4 plays in the regulation of normal gut development through effects on Notch signalling • Although no specific treatment for NEC exists, several potential biological targets have been identified, including growth factors, modifiers of perfusion and novel TLR4 inhibitors with potential translational importance article suggest the need for additional molecular markers to improve early diagnosis of NEC in premature infants. In this regard, the presence of several mol ecules that are detected in the blood have been assessed for their value in establishing the diagnosis of NEC [43] [44] [45] and a number of them have shown considerable promise, including acutephase reactants (such as Creactive protein) and proinflammatory cytokines (for example, TNFα, IL6 and IL8) 45 . In addition, organspecific biomarkers, such as those that would indicate enterocyte injury or intestinal barrier impairment, include intestinal fatty acidbinding protein, liver fatty acidbinding protein, faecal calprotec tin, trefoil factor 3 and claudin3 (REFS 41, 46) . Among these circulating molecules, one of the most promising might be intestinal fatty acid binding protein, a cyto plasmic protein involved in enterocyte lipid metabolism 47, 48 that is released into circulation and secreted into the urine after enterocyte damage, which has been suggested to be useful in the prediction of NEC development 48 and to correlate with the extent of intestinal necrosis 47 . Furthermore, a promis ing strategy in the identification of progressive NEC that requires surgical intervention has been formu lated as a novel algor ithm combining 27 clinical para meters and three urine fibrino gen peptide bio markers, FGA1826, FGA1883 and FGA2659. This algorithm was reported to accurately predict the need for surgery in infants with suspected NEC in 100% of the cases analysed as opposed to only 40.1% when using the clin ical parameters alone 49, 50 , but it remains to be valid ated independently and in larger popu lation studies. These and other biomarkers, therefore, could be considered for use in association with non invasive monitor ing tech niques that assess intestinal tissue perfusion (for example, nearinfrared spectroscopy) 51 to identify those infants at risk of developing NEC.
The use of Doppler ultrasonography to assess perfu sion of the intestinal wall has been suggested to be an accurate screening tool to determine the need for surgical intervention by identifying the presence of bowel necro sis without perforation 52, 53 . Although this strategy has the potential to be more sensitive and specific than detection of the presence of free air in the abdominal cavity by con ventional radiology, the presence of intramural as well as intraluminal air might obscure a reliable interpretation of ultrasonographic images. Furthermore, available data regarding the use of Doppler ultrasonography remains confined to small clinical studies with sample sizes in the range of 26-62 patients 52, 53 . This diagnostic strat egy and others discussed here are promising; however, they remain incompletely proven, so the development of highly sensitive and specific diagnostic tools for NEC continues to be one of the most crucial areas of need in the field.
Medical and surgical treatment
Despite considerable advances in neonatal care, NEC remains a devastating disease that lacks a cure. Current management is largely nonspecific and includes the administration of broadspectrum antibiotics, initiation of bowel rest and the provision of fluid and inotropic support to maintain cardiorespiratory function 2, 5, 39, [54] [55] [56] . Surgical intervention is required in up to 50% of the NEC cases in large, populationbased and hospitalbased multicentre studies coordinated by neonatal research networks 3, 13, 16, 17 and typically includes the removal of necrotic intestine. In rare cases, the placement of a perito neal drain and abdominal irrigation might be sufficient. Although several studies have reported that patients undergoing peritoneal drainage and laparotomy could have similar outcomes 3, 56, 57 , importantly, spontaneous intestinal perforation might resemble the initial pres entation of perforated NEC, thus obscuring the interpret ation of the findings from these studies. Several surgical guidelines have been published 56, [58] [59] [60] . Given that up to 74% of infants initially managed with peritoneal drain age will require a subsequent laparo tomy 3, 59 , a commonly accepted approach has been to reserve primary perito neal drainage for those patients with substantially ele vated intraabdominal pressure that impairs ventilation, or for extremely small infants under 750 g. Additional information based upon the Bell clinical staging criteria is provided in 
Outcomes in infants with NEC
The outcomes in children with NEC are characterized by high overall morbidity, ranging from 20-50% in the USA, as patients experience recurrence, intestinal strictures, short bowel syndrome, growth delay and neurodevelopmental impairment 2, 5 . Infants with NEC have longer hospitalization stays, increased risk of death before discharge and accrue higher financial costs com pared with premature infants without NEC 3, 10 . In the long • Very low birth weight (<1,500 g) 1, 10, 148 • Low Apgar score at 5 min 148 • Formula feeding 37, 125, 149, 150 • Mechanical ventilation 148 • Pathogenesis of NEC Considerable interest has been shown in advancing our understanding of the molecular mechanisms that lead to the development of NEC, to further the development of more precise diagnostic and treatment modalities for this devastating disease. The following paragraphs will review the current theories within the field that seek to explain how NEC develops, and will in particular highlight opportunities for drug discovery based upon the present understanding of its pathogenesis. On the basis of the work of many investigators, we now pro pose a unifying hypothesis for the development of NEC: that the intestine of the premature neonate exists in a hyperreactive state relative to the fullterm intestine, which favours NEC development upon colonization with an appropriate microbial milieu in a patient with a permissive genetic background.
The preterm gut: a susceptible environment for the development of NEC. To understand the reasons for which premature infants are at a particularly high risk of developing NEC compared with fullterm infants, inves tigators have focused their efforts on comprehending the differences between the premature and the fullterm intestinal tract. These studies have outlined important differences in bacterial colonization, micro circulatory perfusion and the maturity of the gastro intestinal immune system 5, 63 . Importantly, although none of these factors alone can completely explain the reasons for which NEC develops, taken together they provide a pic ture that explains the pathogenesis of this disease. These studies also suggest the possibility that a molecular deter minant might have a role in distinguishing the premature from the fullterm intestine. In this regard, increasing evidence suggests that TLR4 is expressed at higher lev els in the premature than the fullterm intestine in mice, humans and other species 64 . Activation of TLR4 on the lining of the premature intestine by the Gramnegative bacteria that colonize the premature gut leads to a num ber of deleterious effects, including increased enterocyte apoptosis, impaired mucosal healing and enhanced pro inflammatory cytokine release, which in aggregate lead to the development of NEC 65 . Moreover, the translocation of Gramnegative bacteria through the gut mucosa leads to activation of TLR4 on the lining of the endothelium of the premature bowel mesentery, resulting in a reduction in blood flow and the development of intestinal ischae mia and necrosis 66 . In additional studies, the elevated expression of TLR4 in the premature gut is reflective of the surprising function TLR4 exhibits in the regula tion of normal gut development in utero via its effects on the Notch signalling pathway and through its expres sion on intestinal stem cells positive for the leucine rich repeatcontaining Gprotein coupled receptor 5 (REF. 64 ). As a consequence of this critical role in normal gut epi thelial development, TLR4 is expressed at high levels in the developing gut; therefore, in the setting of a prema ture birth, intestinal TLR4 levels remain elevated 67 as a consequence of the gut not having completed its full development, as well as perhaps through the ongoing activation by luminal microorganisms. Upon subsequent colonization of the gut by bacteria in the postnatal period, the deleterious consequences of exaggerated TLR4 sig nalling occur, leading to the development of NEC. We term this explanation for the pathogenesis of NEC, in which in utero TLR4 signalling that is required for gut differentiation becomes deleterious in the post natal period, 'the crossswitching hypothesis' . This hypothesis partially explains the reasons for which the premature infant is at risk of NEC develop ment and why the disease occurs upon bacterial coloniza tion. In further support of a role for TLR4 in NEC development, pharmaco logical inhibitors of TLR4 prevent NEC ex vivo in mice and human tissue 68 and breast milk -which is longknown to be an effective preventive agent for patients at risk of NEC development 69, 70 (discussed in detail later in the article) -is a potent inhibitor of TLR4 signalling 71 . Although TLR4 signalling offers an attractive path way to explain the development of NEC, additional factors are known to differ between the premature and fullterm host that might contribute to this disease. A comprehensive list of factors related to prematurity that increase the susceptibility and influence the patho genesis of NEC are presented in BOX 2. The character istics that predispose the premature intestine to NEC include increased molecular expression and signalling activity of key mediators such as TLR4 (REFS 65, (72) (73) (74) (75) , immaturity of cellular and physiological processes such as decreased digestion and absorption of nutrients 76, 77 and impaired intestinal motility [78] [79] [80] . These factors have been identified both in humans with NEC and in experi mental animal models of the disease, discussed later in this section. Among the most critical factors is the high baseline level of cellular endoplasmic reticulum stress within the premature intestine, which increases the likelihood of apoptosis in the epithelial lining compared with the intestinal epithelium of fullterm infants 81 . In addition, the decreased number of mucusproducing goblet cells in the premature intestine results in deficient mechanical protection that leads to increased exposure of the vulnerable epithelia to pathogenic bacteria and toxic luminal contents 64, 82 . The potential for injury resulting from insufficient mucus layer protection is heightened by the impaired clearance of luminal con tents, owing to decreased motility [78] [79] [80] 83 and decreased digestion and absorption as a result of enterocyte imma turity 76, 77 . Other important differences in the intestine of premature infants compared with fullterm infants include increased microvascular tone within the intes tinal mesentery 66, 84 and the presence of immature tight junctions 85, 86 , all of which can render the bowel at risk of proinflammatory signalling, bacterial transloca tion and NEC development 74, 78, 84 . Notably, some of these important factors are linked to TLR4 signalling. For instance, TLR4 hyperactivation in the setting of prematurity leads to reduced goblet cell signalling via activated Notch pathways, and TLR4 activation also reduces endothelial nitric oxide synthase protein levels and activity within the vascular endothelium, leading to reduced mesenteric perfusion and potentially reduced motility 66, 84 . Furthermore, T lymphocytes have been shown to participate in the adaptation of the premature intestinal mucosa to bacterial colonization and contrib ute to NEC development [87] [88] [89] . NEC is associated with lymphocyte imbalance within the intestinal mucosa, as TLR4 signalling in the intestinal epithelium leads to an upregulation of proinflammatory T helper 17 cells and a reduction in protective T regulatory cells, which can be reversed through the administration of retinoic acid in the diet 89 . Although TLR4 is likely to have a critical role in the pathogenesis of NEC, other pathways have been shown to be important. Specifically, various investigators have identified roles for the increased expression and func tion of plateletactivating factor in the mucosal injury and barrier dysfunction associated with NEC 74, 90, 91 , whereas inhibitors of plateletactivating factor protect against NEC development in mouse and rat models 74, 92 . Furthermore, the expression levels of the receptor for platelet activating factor were also increased in mouse and rat ileum 90, 91 . Infants with NEC have high circulating levels of platelet activating factor 90, 93 , associated with the increased expres sion of this protein as well as with deficient activity of plateletactivating factor acetylhydrolase, the enzyme involved in its degrad ation 93, 94 . Consequently, the pres ence of this enzyme in human breast milk 95 has been suggested to contribute to the protective effect associated with breastfeeding 90 . Additionally, platelet activating fac tor has been demonstrated to induce TLR4 expression and signalling 74, 92 . Studies using isolated tissue from infants with NEC as well as from experimental mouse models have implicated a role for intestinal macrophages in the pathogenesis of NEC 96 . Incomplete development of macrophage toler ance to bacterial products within the intestinal lumen, [202] [203] [204] Growth delay 10% 62, 201 • Affected children fall below 50 th percentile for weight and height • Problem more severe in patients with short bowel syndrome after NEC compared with age-matched controls without NEC 201 NEC, necrotizing enterocolitis.
which could breach the barrier as a result of injury to the mucosal epithelia, have been postulated to predispose the preterm human intestine to the develop ment of the disease 96 . Specifically, intestinal macrophages present in the healthy intestinal mucosa of term infants have increased phagocytic and bactericidal activity, but do not produce inflammatory cytokines when challenged by bacterial products, an effect that has been ascribed to the inflammatory downregulation orchestrated by transforming growth factor β2 (REF. 96 ). On the other hand, macrophages present within NEC injury lesions are characterized by a highly inflammatory phenotype, resulting from increased expression of mothers against decapentaplegic homologue 7, an inhibitor of trans forming growth factor β2 signalling 97, 98 . Further studies have suggested a role for impaired Paneth cell function in the development of NEC 99 . Paneth cells are highly specialized secretory cells located within the intestinal crypts of Lieberkühn and are key components of the innate immune system of the small intestine through their release of anti microbial peptides into the intesti nal lumen 100 . Evidence from studies in animal models indicates that Paneth cell depletion in the presence of Klebsiella pneumonia can induce NEClike patho logy 67, [101] [102] [103] . However, given that the newborn gut is reason ably deficient in Paneth cells at baseline, it is unclear what the functional relevance of Paneth cells might be in the disease pathogenesis, although addi tional studies into this potential cellular mechanism of NEC are clearly warranted.
The gut microbiota in NEC pathogenesis. Linking alter ations in the intestinal microflora with the development of various gastrointestinal diseases, including NEC, has received tremendous interest 32, 104 . An important fac tor to consider in the context of NEC is that coloniza tion of the gut in the early neonatal period happens in two waves 105 . The first wave, which is similar in both term and preterm infants, is predominantly dependent upon the mode of childbirth 105, 106 . The second wave of coloniza tion in term infants is determined by feeding type, namely breastfeeding, which is rich in bifido bacteria and Bacteroides, or formulafeeding, which predominantly comprises streptococci, staphylococci and lactobacilli 106 . In the case of preterm infants the sec ond wave of colonization is less influenced by the type of feeding and is characterized by high numbers of Clostridiaceae and Enterobacteriaceae and very low relative numbers of bifidobacteria and Bacteroidetes, in contrast with term infants 105 . In fact, 16S ribosomal RNA gene pyro sequencing has shown that the single most important determinant factor of the composi tion of the premature gut microbiota is the degree of prematurity 107 . A discern ible patterned progression of colonizers from Bacilli to Gammaproteobacteria to Clostridium character izes gut colonization in premature infants but the rate of assembly of the microbial popula tion is dependent upon gestational age: that is, the more premature the infant, the slower the progression of bac terial colonization, yet the same pattern of colonization is followed 107 . These findings demonstrate that host bio logy is an essential modulator of microbiota composition and equilibrium, rather than a passive culture environ ment. Several investigators have shown a link between an abnormal gut microbiota in premature infants and the development of NEC 31, 85, 105, [108] [109] [110] [111] . Additionally, multi ple reports have suggested that functional expres sion of TLRs is critical in the dynamic interaction between the host epithelium and the microbiota that enables success ful intestinal adaptation to the com mensal microbiota [112] [113] [114] . Furthermore, microbial col onization of the gut is required for the development of NEC 115, 116 , as NEC occurs only after this event 5 and can be treated in humans and animal models with broadspectrum antibiotics that target enteric micro organisms 2 . However, whether abnormal bacteria rep resent a cause as opposed to a consequence of NEC is yet to be resolved 115, 117 . Despite multiple reports of NEC outbreaks associated with certain bacteria, identification of a specific pathogen as the main aetiological factor remains elusive 108, 115 . Several studies have shown that decreased diversity exists in the gut microbiota of infants diagnosed with NEC when compared with agematched controls, although without a unified pattern except for the overabundance of strict anaerobes 108, 118, 119 . Many of the studies described in the preceding para graphs have been performed in animal models of NEC and validation of these results in human tissue wherever possible is important. Experimental models of NEC in mice and rats that employ a combination of hypoxia, administration of formula supplemented with bacteria isolated from human NEC stool and exposure to hypo thermia have been the mainstay of many such studies and are roughly comparable to the human disease. Other animal model studies, involving clamping of the mesen teric artery or ablation of Paneth cells 101, 102 , have relevance in certain scientific circumstances and are technically easier to perform. Larger animal models, especially the • Increased baseline levels of endoplasmic reticulum stress within intestinal crypts 81 • Decreased number of mucus-producing goblet cells 163 • Impaired intestinal motility [78] [79] [80] • Decreased digestion and absorption 76, 77 • Enterocyte immaturity 76, 77 • Impaired regulation of microcirculatory perfusion of the gut 66, 84 • Increased bile acid levels and decreased bile acid-binding protein in the intestinal lumen 164 • Tight junction immaturity and impairment 85, 86 • Inefficient antigen processing and presentation 165 • Impaired intestinal regeneration and healing 75 • Discontinuation of gut exposure to amniotic fluid • Increased levels of platelet-activating factor (increased production and decreased degradation) 74, 90, 91 and increased expression of its receptor in the ileum 90, 91 • Decreased FOXP3 + regulatory T cell levels in the small intestine 87, 89, 166 • Decreased levels of intraepithelial lymphocytes expressing the T cell receptor γδ
88
• Decreased intestinal expression of transforming growth factor β2 40, 96 piglet model, share greater similarity to human NEC, but are technically more demanding and costlier to perform 120 . The benefits, drawbacks and challenges of individual models have been reviewed elsewhere 120 .
Strategies for NEC prevention
Given that NEC occurs in a welldefined population of patients -that is, those who are premature -there might be benefit in identifying specific preventive strat egies that, if administered successfully to the appropri ate patients, could reduce the incidence of NEC. In this regard, there has been tremendous interest in develop ing specific nutritional and pharmacological strategies to reduce the incidence of NEC. The most relevant and effective strategies will be reviewed here.
Nutritional approaches for NEC prevention: the use of breast milk. Multiple randomized clinical trials have now validated the empirical observation that breast milk statistically significantly reduces the incidence of NEC 69, 121 . Human milk contains a variety of benefi cial bioactive factors, among which several have been shown to reduce NEC incidence and progression 69, 122 . In BOX 3 we present a list of human milk components and the experimental evidence supporting their pro tective effects. Considerable research efforts have been deployed to identify these critical factors in the hope that new prevent ive strategies can be developed 121 . Although the precise mechanisms by which breast milk protects against NEC are not yet fully understood, emerging experimental evidence suggests that breast milk inhibits TLR4 signalling by preventing glycogen synthase kinase 3β activity 71 . Consequently, breast milk mediated downregulation of TLR4 signalling can reverse the inhib ition of intestinal stem cell proliferation and mucosal healing, which are themselves inhibited by TLR4 64, 71, 123 . Moreover, these effects were shown to be partially dependent upon activation of epidermal growth factor receptor signalling 71 . Whether the development of NEC in association with formula feeding represents the presence of an injurious component in infant formula, or the deficiency of a protective agent only present in breast milk remains to be determined 37, 69, 124 . The lack of avail ability of human breast milk (which can arise for a number of reasons, such as insufficient production by the mother of an infant) remains a major challenge in neonatal care 37, 69 , and has led to the use of donor breast milk as a potential substitute or supplement to formula feeding. Multiple reports support the use of donor human milk as a potentially effective strategy for reducing the incidence of NEC 70, 125 . For those instances in which no human breast milk is available, emphasis has been placed on determining the best evidence based strategies for formulafeeding 37 . Although no specific feeding regimen (that is, composition, vol ume and rate of feeding) has been validated to prevent NEC 37 , the use of standardized feeding guidelines (for example, patientspecific orders with set thresholds to manage feeding intolerance) 126 have been implemented in multi ple centres and have been proven to be effective to reduce the incidence and severity of the disease 126 .
Probiotics in the prevention of NEC. Probiotics are defined as live microorganisms that provide a health benefit to the host 127, 128 . These agents have been shown to protect against NEC and reduce disease severity and overall mortality in premature infants 127, 128 . The finding that a degree of perturbation in the normal gut microbial flora exists in patients with NEC supports a rationale of using probiotics to treat and prevent this disease 105, 115, 116 . Considering the vulnerability of prema ture infants, routine administration of probiotic agents has elicited substantial controversy regarding the type of agent to be used, dosing and timing 128, 129 . A systematic review, analysing 24 trials, evaluated the efficacy and safety of probiotics for preventing NEC 130 and suggested that oral administration of probiotics decreases allcause mor tality and incidence of severe NEC in preterm infants; however, the precise probiotic agent, timing and length of therapy still remains to be established 128, 130 . Emerging consensus is that the use of probiotics in NEC could be effective in reducing the incidence of the disease without increasing rates of sepsis or other adverse events 56, 131, 132 . Mechanistic insights supporting the use of probiotics are scarce but are starting to emerge. Administration of the probiotic bacteria Lactobacillus rhamnosus was shown to increase enterocyte proliferation and differentiation of Paneth cells in enteroids grown in a 3D bioscaffold 133 . Furthermore, treatment with CpGcontaining bacterial DNA, which bypasses the potential adverse effects of live bacteria, is effective against experimental NEC in mice and piglets, and acts by activating Tolllike recep tor 9 and inhibiting TLR4 (REF. 134 ), providing a potential alternative to the use of live probiotics.
Novel pharmacological approaches. Certain biologic agents could have a role in preventing NEC or in treat ing NEC once the disease is established. Heparinbinding EGFlike growth factor has been identified as a biologic agent capable of preventing NEC in various animal models, and of reversing the effects of established NEC, via positive effects on mucosal healing 135 , intestinal stem cell function 136 and vascular perfusion 84, 137 . A readily absorbed and nontoxic oligosaccharide that inhibits TLR4 was shown to prevent NEC in mice and piglets and to reduce • l-arginine 168, 169 • Human milk oligosaccharides and prebiotics 138, 139, [170] [171] [172] • Lactoferrin 121, [173] [174] [175] [176] • Secretory IgA 177 • Platelet-activating factor acetylhydrolase 90, 95 • Growth factors:
-Epidermal growth factor [178] [179] [180] -Heparin-binding EGF-like growth factor [181] [182] [183] -Transforming growth factor β2 intestinal inflammation in ex vivo human intestine obtained during the treatment of NEC 68 . Other investi gators have established an important role for human milk oligo saccharides in NEC prevention and treatment 138, 139 . Additionally, we and others showed that the administra tion of a simulated amniotic fluid might have benefit for the prevention or treatment of NEC, on the basis of the mucosal protection offered by amniotic fluid, which is rich in growth factors and exerts antiTLR4 effects [140] [141] [142] . A sum mary of biological approaches for the prevention of NEC is presented in FIG. 1 . Randomized clinical trials are under way to determine the potential therapeutic and/or preven tive strategies of some of these approaches. In particular, clinical trial NCT00437567 has been designed to evalu ate the effect of the prebiotic galacto oligosaccharide, a component of human milk, in the prevention of NEC 143 . Additionally, clinical trial NCT02405637 aims to evalu ate the efficacy of synthetic amniotic fluid in preventing NEC among verylowbirthweight infants 144 . Emerging evidence also suggests a prophylactic benefit against the development of NEC by oral administration of lacto ferrin with or without probiotics to preterm infants at risk of NEC (gestational age <32 weeks or birth weight <1,500 g) 121 . Although these findings are encour aging, widespread use of these therapies cannot be rec ommended at this point, as the current evidence has been determined to be of moderatetolow quality 121 awaiting the completion of ongoing clinical trials [145] [146] [147] .
Conclusions
NEC is the most common and lethal gastrointestinal pathology that affects premature infants. Characterized by high morbidity and mortality, complex pathogenesis and devastating shortterm and longterm sequelae, it has been dreaded by healthcare providers and famil ies for over a century. Only within the past decade have substantial strides been made in the understanding of the molecular mechanisms that determine NEC patho genesis. These advances undoubtedly hold the promise to improve the development of effective preventive and diagnostic strategies to curtail the devastating con sequences of the disease. Although substantial chal lenges lie ahead to translate the lessons learned at the experimen tal level, continued translational research efforts will certainly provide avenues to alleviate the healthcare and financial burden attributed to NEC. Nature Reviews | Gastroenterology & Hepatology plays an essential part in the development of necrotizing enterocolitis (NEC) by increasing enterocyte and intestinal stem cell apoptosis and impairing mucosal healing through decreased restitution and proliferation. These events lead to disruption of the epithelial barrier, which allows luminal bacteria to translocate and trigger a systemic inflammatory response, sepsis, multiple organ failure and death. Counter-regulatory factors can be exploited in order to dampen TLR4 signalling and expression to prevent the development of NEC. Natural factors include: epidermal growth factor (EGF) 71, 140, 185, 186 , heparin-binding EGF-like growth factor (HB-EGF) [186] [187] [188] , nod-like receptor 2 (NOD2) 189 , Toll-like receptor 9 (TLR9) 67, 190 and platelet-activating factor acetylhydrolase (PAF-AH) 90 . Exogenous factors include: the small-molecule TLR4 inhibitor C34 (REF. 68 ), bacterial (CpG) DNA 67, 190 , muramyl dipeptide (MDP) 189 , sodium nitrate 66 , glutamine 191 , celastrol (also known as tripterine) 192 and dibenzazepine 73 . EGFR, epidermal growth factor receptor; eNOS, endothelial nitric oxide synthase; Hsp70, heat shock protein 70; PAF, platelet-activating factor; SMAC, second mitochondria-derived activator of caspase (also known as Diablo homolog, mitochondrial).
